Journal Article Summary
The article examines the concepts of drug reformulation and repositioning within the pharmaceutical industry, focusing on their implications for market access. This topic is significant because developing new drugs is both expensive and time-consuming, leading companies to seek alternative strategies to maximize the potential of existing medications. By understanding how repositioned or reformulated drugs are evaluated for their added value, the study aims to clarify the criteria that regulators and payers use when considering these products for market approval.
To conduct this research, the authors performed a systematic literature review, identifying and analyzing cases of drug repositioning and reformulation. They retrieved 505 publications, ultimately narrowing it down to 56 relevant articles that detailed 87 unique cases. The findings revealed inconsistencies in how these cases were defined and classified across different studies, indicating a need for standardized terminology to facilitate better analysis and understanding of market access conditions for these drugs.
The study acknowledges several limitations, including the exclusion of in-development or non-approved cases and the potential for new cases to emerge that may not fit the proposed nomenclature. For patients and caregivers, it is essential to discuss with healthcare professionals the implications of drug reformulation and repositioning, especially regarding safety, efficacy, and market access. Understanding these concepts can help patients make informed decisions about their treatment options and the medications they may encounter.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Murteira Susana, Ghezaiel Zied, Karray Slim, Lamure Michel. Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature. Journal of Market Access & Health Policy 2013. DOI: 10.3402/jmahp.v1i0.21131. PMID: 27226826. PMCID: PMC4865745.
Featured Pill Pals Product
Loratadine 10 mg --- 300 Count Bottle --- Generic For Claritin --- Major / Rugby --- Over The Counter
Loratadine 10 mg — 300 Count Bottle — Generic For Claritin — Major / Rugby — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
